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Constitutive Activation of NF-B in Human Hepatocellular
Carcinoma: Evidence of a Cytoprotective Role
LIANG QIAO,1,2 HONGXIA ZHANG,1 JUN YU,1,3 RONA FRANCISCO,1 PAUL DENT,4
MATTHIAS P.A. EBERT,5 CHRISTOPH RÖCKEN,6 and GEOFFREY FARRELL1
ABSTRACT
Activation of nuclear factor-B (NF-B) can promote or inhibit apoptosis. Oxidative stress is an important
mechanism by which certain anticancer drugs kill cancer cells, and is also one of the mechanisms that acti-
vate NF-B. We therefore examined hepatic expression of the NF-B monomer p65 in human hepatocellular
carcinoma (HCC) tissue samples from eight patients and compared it with their respective samples of sur-
rounding liver tissues. We also studied the effect of NF-B inhibition in human HCC cells exposed to oxida-
tive stress, by infecting HuH7 cells with a recombinant adenovirus carrying mutant IB (mIB). Cultured
HuH7 cells were infected with mIB or -galactosidase (-Gal) for 24 hr followed by treatment with in-
creasing concentrations of H2O2. Cytotoxicity, NF-B translocation, NF-B DNA binding, cell proliferation,
and apoptosis were determined. The monomer p65 was overexpressed in six of eight human HCC tissues. In
HuH7 cells, introduction of mIB potently inhibited the translocation, activation, and DNA binding of NF-
B. In control (-Gal-infected) HuH7 cells, exposure to H2O2 produced a dose-dependent increase in apop-
tosis, regardless of NF-B status. mIB-mediated inhibition of NF-B activation sensitized HuH7 cells to
H2O2-induced inhibition of cell growth, and further promoted cell death. Addition of H2O2 (200–500 M) to
control or mIB-infected HuH7 cells enhanced caspase-3 activity and cleavage. Adenovirus-mediated trans-
fer of mIB potently inhibits NF-B activity in HuH7 cells, and this enhances oxidative stress-induced cell
killing.
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INTRODUCTION
ONE OF THE MAJOR CHALLENGES in cancer treatment is theresistance of tumor cells to therapy-induced apoptosis,
which is considered to be the major mode of cell death with
chemotherapeutic agents or radiation therapy. Hepatocellular
carcinoma (HCC) is one of the most common hepatic malig-
nancies worldwide, and its incidence in the United States and
Australia has risen (El-Serag and Mason, 1999; Law et al.,
2000). Because of the poor effects of current treatment modal-
ities, novel approaches of treating HCC are needed.
Oxidative stress is one of the mechanisms by which radia-
tion therapy and certain cancer therapeutic drugs kill cancer
cells. The mechanisms include suppression of cell proliferation
and triggering of cell death, either by apoptosis or necrosis de-
pending on the cellular context and cell type. Nuclear factor-
B (NF-B) is a redox-sensitive transcription factor that is uni-
versally present in all eukaryotic cells. The 90 or so genes that
are governed by NF-B include cytokines and proinflammatory
molecules, cell cycle genes, and genes that either activate and
facilitate cell death process, or oppose it and provide cellular
protection. To avoid inappropriate unleashing of such a bio-
logically pivotal set of consequences, NF-B is normally kept
inactive in the cytoplasm by binding to inhibitory proteins such
as IB (Karin, 1999). Many agents or stimuli such as cytokines,
bacterial products (lipopolysaccharide [LPS]), viruses (e.g., 
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hepatitis C virus [HCV] infection) and their proteins, partial he-
patectomy, tumor necrosis factor- (TNF-), chemotherapeu-
tic agents, and radiation therapy can activate NF-B. On stim-
ulation, IB is phosphorylated at two NH2-terminal serine
residues (S32 and S36) by an IB kinase (IKK) complex; this
permits ubiquitination and targeting to the 26S proteasome
(Henkel et al., 1993; Palombella et al., 1994), where the com-
plex is cleaved to liberate NF-B dimers. These dimeric com-
plexes of NF-B proteins are free to enter the nucleus and bind
to recognition sites that either stimulate or inhibit transcription
of the target genes (Brown et al., 1995).
In many cell types, particularly cancer cells, NF-B is a po-
tent antiapoptotic factor. Deregulation of apoptosis has been im-
plicated in the pathogenesis of HCC complicating chronic 
hepatitis B virus (HBV) and HCV infection (Bantel and
Schulze-Osthoff, 2003; Staib et al., 2003). However, the un-
derlying mechanisms by which apoptosis is downregulated in
the pathogenesis of HCC are incompletely understood. The ef-
fects of NF-B modulation on cell survival depend on both the
cell type and the nature of NF-B inducer (Barkett and Gilmore,
1999). Thus, inactivation of NF-B sensitizes hepatocytes to
TNF-induced apoptosis (Van Antwerp et al., 1996), whereas
after partial hepatectomy, TNF-mediated activation of NF-B
is required for hepatocyte survival and progression into the cell
cycle (Iimuro et al., 1998; Webber et al., 1998; Plumpe et al.,
2000). On the other hand, inhibition of NF-B by its superre-
pressor during experimental obstructive cholestasis does not af-
fect the rate of apoptosis (Bird et al., 2003), and actually sup-
presses hepatic DNA synthesis. In cancer cells, the role of
NF-B inhibition remains even more controversial. Several re-
ports have demonstrated that NF-B inhibition can sensitize
cancer cells, leading to their death by anticancer drugs (Van
Antwerp et al., 1996; Wang et al., 1996, 1999; Feig et al., 1999;
Patel et al., 2000; Arlt et al., 2001), whereas others found that
suppression of NF-B function failed to change the sensitivity
of cancer cells to therapy (Cai et al., 1997; Li et al., 1997; Ben-
tires-Alj et al., 1999). In HCC cells, inhibition of NF-B sup-
presses rather than sensitizes the cells to doxorubicin (Adri-
amycin)-induced apoptosis (Tietze et al., 2000), suggesting that
NF-B may be proapoptotic rather than antiapoptotic in HCC
cells. In our work, however, we demonstrated that rat hepatoma
ARL-6 cells were relatively more resistant to prooxidant H2O2-
induced cell killing compared with normal rat hepatocytes, and
inhibition of NF-B in ARL-6 cells led to sensitization of these
cells to H2O2-induced apoptosis (Qiao et al., 2005). NF-B has
become a new target of gene therapy in many malignant con-
ditions. Some NF-B modulators, especially those with NF-B-
inhibitory capabilities, have been investigated for their efficacy
in enhancing the apoptotic response to therapeutic agents, such
as BAY 11-7082 (Dai et al., 2004) and bortezomib (PS-341)
for the treatment of patients with advanced multiple myeloma
(Voorhees et al., 2003; Panwalkar et al., 2004).
In this study, we aimed to examine whether NF-B inhibi-
tion by mutant IB (mIB) in HuH7 cells (a human HCC
cell line) could facilitate the killing effects of the prooxidant
H2O2 on these cells. mIB has previous been shown to specif-
ically block NF-B activation in many cell types without af-
fecting other transcription factors (Hellerbrand et al., 1998;
Jobin et al., 1998; Feig et al., 1999; Heimberg et al., 2001; Sato
et al., 2003).
The results indicate that abrogation of NF-B activation sen-
sitizes human HCC cells to oxidative stress-induced cell killing
and proliferation inhibition.
MATERIALS AND METHODS
Cell culture
HuH7 cells (derived from a human HCC) were obtained from
the American Type Culture Collection (Cryosite, Sydney, Aus-
tralia). They were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies, Melbourne, Australia)
supplemented with 10% fetal calf serum (FCS), streptomycin
(100 g/ml), penicillin (100 g/ml), and 2 mM L-glutamine in
a humidified atmosphere of 5% CO2 at 37°C.
Hepatic tissues from patients with HCC
We collected malignant (HCC) tissues and their matched sur-
rounding nonmalignant liver tissues from eight patients who
had liver resection for HCC. These tissues were from four pa-
tients with well-differentiated HCC (samples 1–4) and from
four patients with poorly differentiated HCC (samples 5–8), all
with negative HBV and HCV serology. Written consent was
obtained from each patient before tissue collection.
Infection of HuH7 cells with adenoviral vectors
Adenoviral vectors carrying the IB superrepressor
(mIB) or -galactosidase (-Gal) gene were used in this
study. To obtain high-titer viral vectors, 2  107 HEK293 cells
(American Type Culture Collection) were infected at a multi-
plicity of infection (MOI) of 10. The infected cells were main-
tained under routine culture conditions for several days until a
cytopathic effect was evident. Virus-infected HEK293 cells
were collected, and viral particles were released by repeated
freeze–thaw cycles. The resultant crude virus preparation was
purified with a BD Adeno-X virus purification kit (BD Bio-
sciences Clontech, Sydney, Australia), the optical density at 260
nm (OD260) was measured, and the virus titer was determined,
as per the manufacturer’s instructions. HuH7 cells were cul-
tured to 60–70% confluence before being incubated for 4 hr in
serum-free medium with adenoviral vectors carrying mIB or
-Gal. Cells were then cultured in complete growth medium
for up to 24 hr to allow adequate expression of the transgenes
before commencement of further experiments.
Infection efficiency in cultured HuH7 cells was determined
with -Gal as the reporter gene, as described elsewhere (Feig
et al., 1999). The viral infection rate was determined by calcu-
lating the number of 5-bromo-4-chloro-3-indolyl--D-galac-
topyranoside (X-Gal)-stained cells, and by expressing the re-
sults as the ratio of X-Gal-positive cells to the total number of
cells counted. Infection of cells occurred in the expected dose-
dependent manner: with viral concentrations  200 plaque-
forming units (PFU)/cell, HuH7 cells showed virtually no X-
Gal staining, whereas abundant X-Gal-positive cells were
observed with increasing viral concentrations. On the basis of
the X-Gal staining assay, both -Gal and mIB were used at
5000 PFU/cell in most of the subsequent studies unless other-
wise specified.
Determination of viability
After addition of adenoviral vectors and/or H2O2 for 24 hr,
cell viability was determined by 4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1;
Roche Diagnostics, Sydney, Australia) assay, as per the manu-
facturer’s instructions.
Extraction of cytoplasmic and nuclear proteins
Proteins from cytoplasmic and nuclear fractions of cells were
extracted as previously reported (Teoh et al., 2003). Protein
concentrations were estimated with a Bradford protein assay kit
(Bio-Rad, Hercules, CA).
Assessment of NF-kB activation
Activation of NF-B was assessed by two complementary
methods. Immunofluorescence microscopy was used to examine
the translocation of NF-B p65 subunit, as described previously
(Birbach et al., 2002). NF-B DNA-binding activity was deter-
mined by electrophoretic mobility shift assay (EMSA), as reported
elsewhere (Teoh et al., 2002). Supershift was not routinely per-
formed with each experiment, as our laboratory has previously
confirmed the target identity (Teoh et al., 2002).
TdT-mediated dUTP nick end-labeling assay
The TdT (terminal deoxynucleotidyltransferase)-mediated
dUTP nick end-labeling (TUNEL) assay was performed as pre-
viously reported (Qiao et al., 2002) with a commercially avail-
able assay kit (In Situ cell death detection kit; Roche Diagnos-
tics). Briefly, cells were fixed with 3% paraformaldehyde,
incubated with TUNEL reagent for 60 min, rinsed with phos-
phate-buffered saline (PBS), and incubated with Converter-
POD; color was developed by incubation with 3,3-di-
aminobenzidine (DAB) substrate. After counterstaining with
hematoxylin, cells were washed, air dried, mounted, and ex-
amined by light microscopy. The number of TUNEL-positive
cells was counted and the result expressed as the percentage of
positive cells relative to the total number of cells counted.
Determination of protein expression by
immunoblotting: Western blot
Sixty micrograms of protein extract from each sample was
resolved by sodium dodecyl sulfate–12% polyacrylamide gel
electrophoresis (SDS–PAGE) under reducing conditions and
electrotransferred onto nitrocellulose membranes (Millipore,
Bedford, MA), as previously reported (Teoh et al., 2002). The
membranes were blocked with 5% nonfat milk and probed
overnight with primary antibodies against p65, intercellular ad-
hesion molecule-1 (ICAM-1), vascular cell adhesion molecule-
1 (VCAM-1), Bax, and Bcl-XL (Santa Cruz Biotechnology,
Santa Cruz, CA). Membranes were washed and incubated with
species-specific secondary antibodies conjugated with horse-
radish peroxidase, which were detected with SuperSignal West
Pico chemiluminescent substrate (Pierce Biotechnology, Rock-
ford, IL), and exposed to Hyperfilm (Amersham Biosciences,
Castle Hill, Sydney, Australia).
Measurement of caspase-3 activity
Caspase-3 activity was analyzed with an ApoAlert caspase-
3 kit (BD Biosciences Clontech), which measures proteolytic
cleavage of the chromophore p-nitroanilide (pNA). Cells were
harvested, washed with PBS, lysed in ice-cold cell lysis buffer,
and centrifuged at 14,000  g for 15 min. Fifty micrograms of
supernatant was incubated at 37°C for 3 hr in reaction buffer
containing DEVD–pNA. Caspase-3 activity was determined
from the count of pNA released, as determined at 405 nm with
a Wallac 1420 VICTOR2 microplate reader (PerkinElmer, Mel-
bourne, Australia).
Assessment of cell proliferation
Cell proliferation was determined by [3H]thymidine incor-
poration into cellular DNA (Qiao et al., 2001).
Statistical analyses
Results are presented as means  SD. Significant differences
between groups were determined by Student t test.
RESULTS
Expression level of NF-B in human HCC and
nontumorous liver
We compared the expression levels of p65 in eight HCC tis-
sues with their respective levels in surrounding nontumorous
liver by Western blot, and revealed that in six patients, p65 was
expressed at much higher levels in HCC than in nontumorous
tissue (Fig. 1A). In six liver specimens, the constitutive activa-
tion of NF-B p65 was also demonstrated by EMSA (Fig. 1B).
Incidentally, we detected a strong binding complex in the can-
cerous liver of one patient (Fig. 1B). The nature of this com-
plex is not clear. In three cases (patients 3, 4, and 6) in which
p65 was richly expressed, p65 was also detected in the nuclear
compartments of the HCC tissue (but not in nontumorous liver)
(Fig. 1C), indicating constitutive activation. The average ex-
pression level of NF-B was not significantly different between
well and poorly differentiated HCCs.
Expression level of NF-B in HuH7 cells versus
nontumorous liver
As HuH7 cells were derived from human HCC, we also com-
pared the basal expression level of NF-B p65 in this cell type
with that in nontumorous tissues obtained from two patients
who had liver resection for HCC. By Western blot, p65 was
also found to be richly expressed in HuH7 cells compared with
two samples of nontumorous tissue (Fig. 1D). EMSA also dem-
onstrated constitutive activation of NF-B in HuH7 cells com-
pared with noncancerous hepatic tissues (Fig. 1D, arrowhead).
These data suggested that NF-B is either overexpressed
and/or constitutively activated in most HCC tissues.
Infection efficiency of adenoviral vectors in 
HuH7 cells
On the basis of the above results, we attempted to block NF-
B activity in HCC cells by adenovirus-mediated transfer of
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FIG. 1. (A) Western blot of basal expression of NF-B p65 in homogenates of human HCC tissue (T) and of surrounding non-
tumorous liver tissue (N) from eight patients. (B) Constitutive activation of NF-B p65 in six malignant liver tissues and their
respective nonmalignant tissues. (C) Detection of NF-B p65 in the nuclear protein of three human HCC tissues and their non-
tumorous liver tissues. (D) Basal levels of NF-B p65 in HuH7 cells and in two nontumorous liver tissues. In each Western blot,
-actin was used as a loading control. Results are representative of three repeated experiments.
0
X-
ga
l p
os
itiv
e 
ce
lls
 (%
)
120 D
100
80
60
40
20
0
100 200 500 1000
Viral dose (pfu/cell)
2000 100005000
A B C
FIG. 2. Infection efficiency of adenoviral vec-
tor, determined by X-Gal staining. (A–C) Rep-
resentative photographs of X-Gal staining. HuH7
cells were grown to 60% confluence and infected
with -Gal at 0 (A), 2000 (B), and 5000 (C)
PFU/cell for 24 hr, followed by X-Gal staining.
Blue-stained cells indicate the presence of the -
galactosidase gene. Results are representatives of
at least three experiments. (D) The number of X-
Gal-positive (blue) cells was counted, and ex-
pressed as the percentage of total cells. The re-
sults shown represent the means of three separate
experiments performed in duplicate.
mIB and to determine whether this construct could facilitate
growth inhibition and cell death in response to oxidative stress.
Initially, we used three different HCC cell lines: HuH7, HepG2,
and Hep3B. As the results obtained from these three cell lines
were similar, we performed most of the experiments only in
HuH7 cells, and the reported data are mostly from this cell line.
To determine the in vitro infection efficiency of HCC cells
by mIB, we used an adenovirus carrying -galactosidase (-
Gal) as a reporter to determine the number of successfully in-
fected cells. Figure 2 shows the representative results obtained
in HuH7 cells. Twenty-four hours after infection with -Gal
adenovirus at various concentrations, cells were viewed by light
microscopy, and positively infected cells were determined by
X-Gal staining. Cells infected with virus at concentrations be-
low 200 PFU/cell virtually did not show any X-Gal-positive
staining. More X-Gal-positive cells were observed with in-
creased viral concentrations above 500 PFU/cell, and the vast
majority of cells (95%) expressed -Gal after being infected
with 5000 PFU/cell (Fig. 2D). Figure 2A–C show represen-
tative photographs of X-Gal staining.
Effects of adenoviral infection of HuH7 cells
A single band, of atomic mass 36 kDa, was present in lysates
of mIB-infected HuH7 cells, whereas in lysates of cells in-
fected with -Gal no such protein band was observed (Fig. 3A).
As the promoter driving IB expression is also transcription-
ally regulated by NF-B (Greten and Karin, 2004; Monks et
al., 2004), ectopic expression of mIB also inhibited endoge-
nous expression of IB (Fig. 3A), so that the expression level
of mIB exceeded endogenous IB expression more than
10-fold. As expected, there was no degradation of mIB af-
ter addition of H2O2 (Fig. 3B).
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FIG. 3. Expression of mIB in HuH7 cells. (A) Cells were
infected with vehicle (Con) or with adenovirus expressing
mIB or -Gal at 2000 and 5000 PFU/cell for 24 hr. (B) Cells
were infected with adenovirus expressing either mIB or -
Gal, each at 5000 PFU/cell for 24 hr, followed by treatment
with various concentrations of H2O2 for 24 hr. Western blot
analysis was performed with polyclonal antibodies against
IB. -Actin was used as a loading control. The results are
representative of three separate experiments.
Nuclear translocation of p65 is an essential step for NF-
B activation. We therefore examined the effect of mIB
on p65 translocation. In naive HuH7 cells, p65 was localized
virtually entirely in the cytoplasmic compartment (Fig. 4A
and C), and mIB slightly reduced the basal level of p65
expression, as revealed by Western blot (Fig. 4A). The inhi-
bition of p65 translocation by mIB appeared to be dose de-
pendent (Fig. 4B), with mIB at 5000 PFU/cell almost com-
pletely abrogating p65 translocation. Further studies showed
that in cells infected with -Gal, addition of 500 M H2O2
for 24 hr provoked translocation of p65 to the nucleus (Fig.
4D), and this translocation was profoundly inhibited by
mIB (Fig. 4E). By EMSA, inhibition of NF-B transloca-
tion led to reduced DNA binding (Fig. 4F). In cells infected
with -Gal followed by H2O2 treatment, a specific band cor-
responding to NF-B p65 was evident, whereas in cells in-
fected with mIB, NF-B DNA binding was suppressed.
Similar to Western blot findings, mIB at 5000 PFU/cell al-
most completely abolished NF-B DNA-binding activity.
These findings for p65 were also observed for p50 (data not
shown).
As H2O2-induced p65 nuclear translocation occurred in a
dose-dependent manner, and cell death was profound after ex-
posure to 1000 M H2O2, we chose 500 M H2O2 for subse-
quent experiments unless otherwise specified.
Inhibition of NF-B by mIB downregulates NF-B
target genes
To confirm that the introduced mIB functionally blocked
NF-B-regulated genes in HuH7 cells, we performed Western
blot analysis of intracellular adhesion molecule-1 (ICAM-1). In
mIB-infected cells compared with -Gal-infected cells, the
basal levels of ICAM-1 was reduced (Fig. 4G), and the H2O2-
induced increase in ICAM-1 was strongly inhibited (Fig. 4H).
Similar results were found with another NF-B target gene,
VCAM-1 (data not shown).
Effects of NF-B inhibition on proliferation of 
HuH7 cells
Inhibition of NF-B by mIB did not, itself, significantly
suppress cell proliferation (Fig. 5A). Exposure of cells to lower
concentrations of H2O2 (between 1 and 200 M) did not sig-
nificantly affect cellular DNA synthesis (Fig. 5B). However,
inhibition of NF-B accentuated such suppression when cells
were exposed to higher doses of H2O2 (500 M) (Fig. 5B).
Effect of NF-B inhibition on viability of HuH7 cells
Because NF-B activation favors cell survival, we investi-
gated whether blocking NF-B sensitized HuH7 cells to ox-
idative stress-induced cell killing. In cells infected with either
-Gal or mIB, incubation of cells with H2O2 for 24 hr caused
a dose-dependent loss of cell viability. This was substantially
greater in cells infected with mIB (Fig. 6). Because the ear-
lier studies showed that this concentration of H2O2 potently ac-
tivates NF-B DNA-binding activity, these results are consis-
tent with the proposal that NF-B is an important survival factor
for maintaining HuH7 cells.
Apart from H2O2, we also used bleomycin, a chemotherapeu-
tic agent that causes marked oxidative stress to target cells, to test
whether inhibition of NF-B could sensitize the cell-killing effect
of this agent. As revealed by WST-1 assay, cells infected with
mIB were more sensitive to bleomycin-induced killing as com-
pared with cells infected with -Gal (data not shown).
Effects of NF-B inhibition on apoptosis in 
HuH7 cells
As shown by TUNEL staining, 500 M H2O2 caused mas-
sive apoptotic cell death in HuH7 cells (Fig. 7C). Blockade of
NF-B failed to increase the rate of apoptosis (Fig. 7D). On the
contrary, apoptotic cell death appeared to be suppressed (Fig.
7E), although the difference between these two groups was not
significant. Judging by morphology, cell death in both groups
was also via necrosis. More necrotic cells were present in
mIB-infected cells than in -Gal-infected cells.
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dependent experiments performed in duplicate.
Mechanisms of cell killing in response to oxidative
stress and NF-B inhibition
Finally, we investigated the possible mechanisms responsi-
ble for apoptotic cell death in response to oxidative stress and
NF-B inhibition. We tested whether caspase-3 was activated.
As shown in Fig. 8A, caspase-3 was dose dependently activated
by 200 and 500 M H2O2, and blockage of NF-B caused more
caspase-3 activation. Western blot confirmed this finding,
showing a more marked decrease of procaspase-3 in mIB-
infected cells treated with H2O2 (Fig. 8B).
We also measured the expression of two Bcl-2 family pro-
teins: the proapoptotic Bax and anti-apoptotic Bcl-XL. Bax ex-
pression was not altered by viral infection alone or viral infec-
tion followed by H2O2 (Fig. 8C). In contrast, the expression of
Bcl-XL was suppressed by 500 M H2O2, and mIB further
suppressed its expression (Fig. 8C).
DISCUSSION
Activation of the ubiquitous transcription factor NF-B is
protective against cell death in many cell types, particularly (but
not exclusively) by apoptosis (Karin and Lin, 2002). It is there-
fore of interest that many cancers, such as breast cancer, lung
cancer, and lymphoma (Rayet and Gelinas, 1999), and HCC
(according to other reports), constitutively express high levels
of NF-B (Kaufmann and Earnshaw, 2000; Herr and Debatin,
2001; Chiao et al., 2002). Conversely, several anticancer drugs
potently activate NF-B, and resistance of certain cancer cells
to apoptosis has been attributed to constitutive activation of NF-
B (Chiao et al., 2002; Sato et al., 2003; Panwalkar et al., 2004;
Samanta et al., 2004). In the present study, we found that at
least six of eight human HCCs (75%) expressed higher levels
of the NF-B Rel protein, p65, than surrounding noncancerous
liver, and in at least three of them, this p65 was localized pre-
dominantly in the nucleus. The latter finding is consistent with
constitutive activation of NF-B. Thus the present results con-
firmed and extend earlier studies of high-level NF-B in HCC
liver and show apparently constitutive activation of NF-B in
human HCC. We also found no difference between well and
poorly differentiated HCC in terms of NF-B protein expres-
sion. This is in agreement with a previous report (Guo et al.,
2005).
Because it is difficult to study the mechanisms and biologi-
cal implications of NF-B activation in intact human liver, we
addressed these issues in an HCC cell line, HuH7, which also
expresses high-level constitutive activation of NF-B. In this
study, we used mIB (also termed IB superrepressor),
transfected via an adenoviral vector, to block NF-B activation,
and examined the effect on cell viability, mechanisms of cell
death (especially apoptosis), and proliferation. At the doses that
were effective in these experiments, mIB could easily be in-
troduced into the HuH7 cells without having any detrimental
effects on cell viability or endogenous NF-B. Expression lev-
els of mIB were readily induced up to 10-fold higher than
the level of endogenous IB. As expected, this protein was
not degraded after addition of H2O2. Further, the expression of
endogenous IB, which is itself under NF-B regulation, was
also inhibited by mIB.
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FIG. 5. Effect of NF-B inhibition on cell pro-
liferation. (A) HuH7 cells were infected for 24 hr
with -Gal or mIB at 5000 PFU/cell. (B) Cells
were infected for 24 hr with -Gal or mIB at
5000 PFU/cell followed by exposure to H2O2
for 24 hr. DNA synthesis was measured by
[3H]thymidine incorporation, as described in de-
tail in Materials and Methods. Each column rep-
resents the average -scintillation count of three
separate experiments performed in triplicate. 
*p  0.05.
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FIG. 6. Effect of NF-B inhibition on viability of HuH7 cells
exposed to H2O2. At the end of treatment, cell viability was de-
tected by WST-1 assay, as described in Materials and Methods.
*p  0.05. Results represent the means of three separate mea-
surements with nine replicates.
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In untreated HuH7 cells, most p65 is located in the cyto-
plasm. Introduction of mIB effectively prevented H2O2-in-
duced p65 translocation to the nucleus, as judged by Western
blot and immunofluorescence staining, and confirmed NF-B
p65/p50 dimeric binding to DNA by EMSA. Such abrogation
of NF-B activation caused the anticipated functional conse-
quences of downregulation of two important downstream tar-
get genes, ICAM-1 and VCAM-1.
Previous studies of patients with HCC have shown a marked
increase in circulating (Hyodo et al., 1996) and hepatic (Yoong
et al., 1998) expression of these cell adhesion molecules, as well
as E-selectin. In the present study, we showed that ICAM-1 is
highly expressed in HuH7 cells. However, the relationship be-
tween the expression of cell adhesion molecules and cancer de-
velopment or prognosis remains controversial. It is therefore un-
clear whether modulation of ICAM-1 and VCAM-1 expression
by manipulating NF-B activity would potentially be useful in
controlling the local progression of liver cancer, or metastasis
from the liver.
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FIG. 7. Detection of apoptosis by TUNEL staining. HuH7
cells were infected at 5000 PFU/cell with -Gal (C) or mIB
(D) for 24 hr, followed by treatment with 500 M H2O2 for 24
hr. (A) Negative control (no TdT was included in the reaction).
(B) Experimental positive control (cells treated with DNase I
for 10 min). Arrowheads represent TUNEL-positive cells, and
arrows indicate TUNEL-negative cells. Photographs are repre-
sentative of three separate experiments. (E) Quantitative anal-
ysis. NS, no significant difference.
FIG. 8. Effect of NF-B inhibition on caspase-3, Bax, and
Bcl-2 expression. (A) Caspase-3 activity was determined in
lysates of cells that were infected with or without -Gal or
mIB at 5000 PFU/cell for 24 hr followed by treatment with
0, 200, and 500 M H2O2 for 24 hr. Each column represents
the mean of three separate experiments performed in triplicate.
*p  0.05. (B) Western blot of caspase-3 in the same samples.
(C) Protein expression of Bax and Bcl-XL. -Actin was used
as a loading control. Results shown are representative blots of
three separate experiments.
The human liver is constantly exposed to oxidative stress
produced as the result of the metabolic production of reactive
oxidative species (ROS), such as hydrogen peroxide, superox-
ide ion, and hydroxyl radicals. ROS can cause oxidative dam-
age to DNA and is therefore a potential mutagenic factor in
cancer formation and, in addition, can modulate cell prolifera-
tion and cell death in ways that could promote clonal expan-
sion of preneoplastic foci in the liver. On the other hand, some
cancer-therapeutic agents kill cells by inducing oxidative stress
in mitochondria, a pathway that is opposed by ROS-induced
activation of NF-B. Many apoptotic stimuli, such as calcium
ionophore, TNF, interleukin-1, and lipopolysaccharide, can ac-
tivate NF-B by distinct intracellular pathways, but a common
mechanism involves the synthesis of ROS (Schreck et al.,
1991). Thus, NF-B is a redox-sensitive nuclear transcription
factor. Studies have shown that raised intracellular H2O2 lev-
els are mechanistically responsible for induction of apoptosis
and inhibition of growth in MG132 (an inhibitor of 26S pro-
teasome)-treated HCC cells (Tuvdendorj et al., 2003) as well
as in arsenic trioxide-treated acute promyelocytic leukemic cells
(Chen et al., 2003). The role of NF-B and ROS in chemically
induced hepatocarcinogenesis was supported in one study
(Maeda et al., 2005).
In the present study, treatment of HuH7 cells with H2O2 led
to dose-dependent cell killing that was enhanced by NF-B in-
activation. Cell killing was via both apoptosis and necrosis. The
fact that blockade of NF-B activity by mIB potentiated
H2O2-induced cell death via apoptotic and nonapoptotic path-
ways is consistent with growing evidence that NF-B not only
regulates the apoptotic pathways but may also govern pathways
that lead to necrosis (Kucharczak et al., 2003). In addition, ne-
crosis might be secondary to the apoptosis (“necrogenic apop-
tosis”), occurring in response to apoptotic stimuli (Xu et al.,
1998). It seems increasingly likely that at certain stages of their
pathways, and particularly in the liver, where the requirement
for ATP to execute apoptosis may be high, these two different
types of cell death share the same signaling events.
Apoptosis appeared not to be the major mode of cell death
when HuH7 cells were exposed to H2O2. However, the further
accentuation of cell death attributed to NF-B blockade in the
face of H2O2 was not apparently by apoptosis. Caspase-3 plays
an essential role in apoptosis execution in most cell types, and
exposure of HuH7 cells to H2O2 caused a dose-dependent in-
crease in caspase-3 activity. Blocking NF-B further potenti-
ated H2O2-induced activation of caspase-3. However, caspase-
3 can also play a role in necrosis under some circumstances
(El-Hassan et al., 2003), especially when ATP is depleted as
may be the case in HuH7 cells exposed to H2O2. Alternatively,
the further accentuation of cell death, which was also not as-
sociated with TUNEL-positive cells, could be due to necrosis.
There are many target genes of NF-B, include such anti-
apoptotic proteins as cIAP1, cIAP2, TRAF1, TRAF2, Bcl-XL,
and FLIP, and certain proapoptotic proteins such as Bax, Fas,
Fas ligand, TRAIL-R1, and TRAIL-R2 (Wang et al., 1999; 
Tietze et al., 2000; Heimberg et al., 2001; Sato et al., 2003;
Debatin, 2004). It is therefore possible that activation of 
NF-B can inhibit or promote apoptosis. Bax is a strong
proapoptotic gene whereas Bcl-XL possesses strong antiapop-
totic properties. In our study, Bax was not affected by NF-B
modulation in HuH7 cells. However, inhibition of NF-B ac-
tivity appeared to suppress Bcl-XL expression. Therefore, we
speculated that diminished expression of Bcl-XL may have con-
tributed to increased apoptosis.
NF-B is important not only in apoptosis pathways, but also
as a transcription factor in the signal transduction of the inflam-
matory response; this is particularly relevant in cancers in which
inflammation plays a pivotal role. The relationship between in-
flammation and cancer has gained extensive attention (Balkwill
and Coussens, 2004; Karin and Greten, 2005; Li et al., 2005).
Chronic inflammation has been recognized as an important cause
of tumor development, accounting for approximately 20% of hu-
man cancer. It has been proposed that NF-B contributes to tu-
morigenesis through effects on both tumor cells and tumor-
associated inflammatory cells (Balkwill and Coussens, 2004). 
Inhibition of NF-B in malignant cells would increase suscepti-
bility to apoptosis-inducing agents, through the downregulation
of certain antiapoptosis factors such as Bcl-XL, and in inflam-
matory cells it would inhibit the expression of growth and sur-
vival factors such as TNF- and IL-6. Thus, targeting NF-B
could be a useful strategy for cancer therapy (Karin and Greten,
2005).
The effect of NF-B superrepressor in experimental cancer
therapy has been demonstrated in several studies. In one study
of hepatocarcinogenesis in multidrug resistance-2 gene (MDR2)
knockout mice (Pikarsky et al., 2004), it was found that the in-
flammatory process triggers hepatocyte NF-B through upreg-
ulation of tumor necrosis factor- (TNF-) in adjacent endo-
thelial and inflammatory cells. Although inhibition of NF-B in
mice by tetracycline-inducible, liver-specific expression of a su-
perrepressor of NF-B did not affect the course of hepatitis, or
the early phases of hepatocyte transformation, IB superrepres-
sor-mediated suppression of NF-B did result in the apoptosis
of transformed hepatocytes and suppressed progress to hepato-
cellular carcinoma, suggesting that NF-B may not be required
for early-phase cancer development (tumor initiation), but is es-
sential for subsequent tumor promotion. Similarly, inhibition of
NF-B by superrepressor reduces the inflammation-induced me-
tastasis of CT26 colon cancer cells to the lungs (Luo et al., 2004).
Our in vitro results support the idea that NF-B superrepressor
may be a potentially useful approach in targeting NF-B as a
therapeutic tool for certain cancer, especially those malignan-
cies that are closely associated with inflammatory or oxidative
stress processes.
One of the aims of cancer therapy is to deprive cancer cells
of their growth potential. In this study, we showed that inhibi-
tion of NF-B did not, by itself, suppress cell proliferation (as
indicated by DNA synthesis) in HuH7 cells. However, block-
ing NF-B by mIB did enhanced the growth-inhibitory ef-
fect of H2O2, especially when it was used at higher doses. Fur-
ther studies are needed to clarify what genes are responsible for
such growth inhibition.
In conclusion, the current study demonstrated that adenovi-
rus-mediated transfer of mIB is an efficient way to block the
NF-B pathway in vitro. The introduced construct is functional
in that it blocks NF-B translocation, blocks DNA binding, and
inhibits the expression of downstream target genes. Inhibition
of NF-B by mIB has the potential to inhibit HuH7 cell pro-
liferation, and oxidative stress can strongly activate the apop-
totic cascade in HuH7 cells. These results warrant further stud-
ies into the efficacy and mechanisms of NF-B inactivation as
a new target for HCC gene therapy. Our preliminary in vivo re-
sults have indicated that HuH7 cells infected with mIB
showed diminished tumorigenic potential in nude mice. We
await the completion of this study.
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